All In MedTech

FDA Clearance Tracker · P170034-S013

Hydrus Microstent

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 30, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 30, 2025

Approved

Time to decision

112 days

Received Oct 10, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P170034-S013
Device name
Hydrus Microstent
Applicant location
Fort Worth, TX
Received
Oct 10, 2024
Decided
Jan 30, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P170034

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code OGO

FDA's approval statement

As written in FDA's record.

approval for minor corrections to labeling that reflects the findings of the Post-Approval Study (PAS) designated as “Continuation of Premarket Cohort PAS” or P170034/PAS 001.

Source documents

Other decisions for Alcon Research, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.